Eliane Tang1, Lucien Lahmi2, Nicolas Meillan2, Gianandrea Pietta2, Sébastien Albert3, Philippe Maingon2. 1. Department of Radiation Oncology, groupe Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, 47-83, boulevard de l'Hôpital, 75013, Paris, France. eliane.tang@gmail.com. 2. Department of Radiation Oncology, groupe Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Sorbonne Université, 47-83, boulevard de l'Hôpital, 75013, Paris, France. 3. Department of Head and Neck Surgery, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France.
Abstract
PURPOSE OF REVIEW: Management of metastatic head and neck squamous cell cancers (HNSCC) can be challenging. This review gives an insight of current treatment options for patients with synchronous metastatic HNSCC and suggests a therapeutic algorithm. RECENT FINDINGS: With the rise of novel therapeutic techniques and medications, many treatment options for both locoregional and distant metastatic disease have become available. The evolving paradigm of metastatic disease now integrates the concept of oligometastatic disease. On top of systemic treatments, patients with low metastatic burden can benefit from curative approaches such as local therapies (surgery, radiotherapy) directed to either primary tumour and distant metastasis. However, data integrating these considerations in the management of metastatic HNSCC is still lacking. Based on this algorithm, we can provide a tailored treatment to each patient with synchronous metastatic HNSCC, according to their age, general condition and metastatic burden.
PURPOSE OF REVIEW: Management of metastatic head and neck squamous cell cancers (HNSCC) can be challenging. This review gives an insight of current treatment options for patients with synchronous metastatic HNSCC and suggests a therapeutic algorithm. RECENT FINDINGS: With the rise of novel therapeutic techniques and medications, many treatment options for both locoregional and distant metastatic disease have become available. The evolving paradigm of metastatic disease now integrates the concept of oligometastatic disease. On top of systemic treatments, patients with low metastatic burden can benefit from curative approaches such as local therapies (surgery, radiotherapy) directed to either primary tumour and distant metastasis. However, data integrating these considerations in the management of metastatic HNSCC is still lacking. Based on this algorithm, we can provide a tailored treatment to each patient with synchronous metastatic HNSCC, according to their age, general condition and metastatic burden.
Entities:
Keywords:
Chemotherapy; Head and neck cancer; Metastases; Radiotherapy; Squamous cell cancer; Treatment algorithm
Authors: K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison Journal: N Engl J Med Date: 2010-06-07 Impact factor: 91.245
Authors: Jussuf T Kaifi; Niraj J Gusani; Isabelle Deshaies; Eric T Kimchi; Michael F Reed; Rickhesvar P Mahraj; Kevin F Staveley-O'Carroll Journal: J Surg Oncol Date: 2010-08-01 Impact factor: 3.454
Authors: Rajal A Patel; Jonathan B Bell; Thomas Kim; Mark Agulnik; James P Chandler; Bharat B Mittal; Tim J Kruser Journal: J Neurooncol Date: 2017-05-25 Impact factor: 4.130
Authors: Shao Hui Huang; Bayardo Perez-Ordonez; Fei-Fei Liu; John Waldron; Jolie Ringash; Jonathan Irish; Bernard Cummings; Lillian L Siu; John Kim; Ilan Weinreb; Andrew Hope; Patrick Gullane; Dale Brown; Willa Shi; Brian O'Sullivan Journal: Int J Radiat Oncol Biol Phys Date: 2010-10-13 Impact factor: 7.038